DOSING REGIMEN FOR BCMAx-CD3 ANTIBODIES CONSTRUCTS
AssigneesAmgen Research (Munich) GmbH, Amgen Inc.
InventorsGerhard Zugmaier, Max Topp, Gerd Munzert
Life of this patent
Estimating the term…
Loading patent…
AssigneesAmgen Research (Munich) GmbH, Amgen Inc.
InventorsGerhard Zugmaier, Max Topp, Gerd Munzert
Estimating the term…
The present invention relates to an antibody construct comprising a first domain which binds to BCMA and a second domain which binds to CD3, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a specified dose in at least one cycle, wherein one cycle comprises a specified period of administration of the antibody construct. Moreover, the invention relates to a method for the treatment of a BCMA positive neoplasm comprising administering a specified amount of such antibody construct, and the use of such antibody construct for the manufacture of a medicament for the treatment of a BCMA positive neoplasm.
An antibody construct comprising a first domain which binds to BCMA and a second domain which binds to CD3, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a dose of 6.5 μg/day up to 650 μg/day in at least one cycle, wherein one cycle comprises a period of administration of the antibody construct of at least seven consecutive days.
The antibody construct according to any one of the preceding claims, wherein one cycle comprises a period of administration of the antibody construct, followed by a period without administration of the antibody construct.
The antibody construct according to any one of the preceding claims, wherein the period of administration of the antibody construct is from one to eight weeks, preferably from two to six weeks, and more preferably from 25 to 30 days.
The antibody construct according to any one of claims 3 to 6, wherein the period without administration of the antibody construct is from one week to three months, preferably from one week to two months, and more preferably from one week to one month.
The antibody construct according to any one of the preceding claims, wherein the dose of the antibody construct is constant during each cycle.
The antibody construct according to any one of the preceding claims, wherein the dose of the antibody construct is constant during each cycle and from one cycle to the subsequent cycle.
The antibody construct according to any one of the preceding claims, which is administered parenterally, preferably intravenously, and more preferably via continuous intravenous administration.
The antibody construct according to any one of the preceding claims, wherein the BCMA positive neoplasm is selected from the group consisting of multiple myeloma, relapsed and/or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary myeloma, plasmacytoma, plasma cell leukemia, Waldenström's macroglobulinemia, and smoldering myeloma.
The antibody construct according to any one of the preceding claims, wherein
The antibody construct according to any one of the preceding claims, which competes for binding to BCMA with or which binds to the same epitope of BCMA as:
The antibody construct according to any one of the preceding claims, which competes for binding to CD3 with or which binds to the same epitope of CD3 as:
The antibody construct according to any one of the preceding claims, wherein the first domain which binds to BCMA comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from:
The antibody construct according to any one of the preceding claims, wherein the first domain which binds to BCMA comprises a VH region having an amino acid sequence selected from the group consisting of those depicted in SEQ ID NOs:
The antibody construct according to any one of the preceding claims, wherein the first domain which binds to BCMA comprises a VL region having an amino acid sequence selected from the group consisting of those depicted in SEQ ID NOs:
The antibody construct according to any one of the preceding claims, wherein the first domain which binds to BCMA comprises a VH region and a VL region selected from the group consisting of:
The antibody construct according to any one of the preceding claims, wherein the first domain which binds to BCMA comprises or consists of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:
The antibody construct according to any one of the preceding claims, wherein the second domain which binds to CD3 comprises a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of:
The antibody construct according to any one of the preceding claims, wherein the second domain which binds to CD3 comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 selected from the group consisting of:
The antibody construct according to any one of the preceding claims, wherein the second domain which binds to CD3 comprises a VL region comprising CDR-L1, CDR-L2 and CDR-L3 and a VH region comprising CDR-H1, CDR-H2 and CDR-H3 selected from the group consisting of:
The antibody construct according to any one of the preceding claims, wherein the second domain which binds to CD3 comprises a VL region having an amino acid sequence selected from the group consisting of those depicted in SEQ ID NO:
The antibody construct according to any one of the preceding claims, wherein the second domain which binds to CD3 comprises a VH region having an amino acid sequence selected from the group consisting of those depicted in SEQ ID NO:
The antibody construct according to any one of the preceding claims, wherein the second domain which binds to CD3 comprises a VL region and a VH region selected from the group consisting of:
The antibody construct according to any one of the preceding claims, wherein the second domain which binds to CD3 comprises or consists of a polypeptide having an amino acid sequence selected from the group consisting of those depicted in SEQ ID NOs:
The antibody construct according to any one of the preceding claims, which comprises a polypeptide having an amino acid sequence selected from the group consisting of those depicted in SEQ ID NOs:
Dependencies are inferred from the claim text.